The Hidden Impact of GLP-1 Receptor Agonists on Endometrial Receptivity and Implantation

Overview

Journal Acta Obstet Gynecol Scand

Publisher Wiley

Specialty Gynecology & Obstetrics

Date 2024 Dec 19

PMID 39696822

Authors

Alberto Sola-Leyva

Amruta D S Pathare

Apostol Apostolov

Elina Aleksejeva

Keiu Kask

Triin Tammiste

Susana Ruiz-Duran

Sanjiv Risal

Ganesh Acharya

Andres Salumets

Affiliations

Soon will be listed here.

Abstract

Increasing infertility rates represent a growing medical challenge in modern societies resulting from a complex interplay of sociocultural trends, lifestyle factors, exposure to environmental toxins, and underlying health problems. Women's fertility is particularly vulnerable to these shifts. The obesogenic lifestyle not only accelerates weight gain, but also disrupts ovulation driving the rise in infertility. Among several medications used for treating obesity and type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1RAs) show promising improvement in female fertility most likely by stimulating ovulation. However, the effects of GLP-1RAs on the endometrium remain unclear. Further studies are needed to investigate the impact of GLP-1RAs on endometrial receptivity and embryo implantation and early development. The aim of this study is to address the knowledge gap regarding the effects of GLP-1RAs on human reproduction, with special focus on the endometrium. Understanding these mechanisms may help to develop new strategies for improving fertility treatment, reduce implantation failure and address potential safety concerns regarding teratogenicity and adverse developmental outcomes for children born to women conceiving during or soon after GLP-1RA treatment.

Citing Articles

Exploring the Immunological Aspects and Treatments of Recurrent Pregnancy Loss and Recurrent Implantation Failure.

Garmendia J, De Sanctis C, Hajduch M, De Sanctis J Int J Mol Sci. 2025; 26(3).

PMID: 39941063 PMC: 11818386. DOI: 10.3390/ijms26031295.

The hidden impact of GLP-1 receptor agonists on endometrial receptivity and implantation.

Sola-Leyva A, Pathare A, Apostolov A, Aleksejeva E, Kask K, Tammiste T Acta Obstet Gynecol Scand. 2024; 104(2):258-266.

PMID: 39696822 PMC: 11782050. DOI: 10.1111/aogs.15010.

References

Boretto M, Maenhoudt N, Luo X, Hennes A, Boeckx B, Bui B . Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nat Cell Biol. 2019; 21(8):1041-1051. DOI: 10.1038/s41556-019-0360-z. View

Drucker D . The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metab. 2016; 24(1):15-30. DOI: 10.1016/j.cmet.2016.06.009. View

Shibata S, Endo S, Nagai L, H Kobayashi E, Oike A, Kobayashi N . Modeling embryo-endometrial interface recapitulating human embryo implantation. Sci Adv. 2024; 10(8):eadi4819. PMC: 10889356. DOI: 10.1126/sciadv.adi4819. View

Janesick A, Shelansky R, Gottscho A, Wagner F, Williams S, Rouault M . High resolution mapping of the tumor microenvironment using integrated single-cell, spatial and in situ analysis. Nat Commun. 2023; 14(1):8353. PMC: 10730913. DOI: 10.1038/s41467-023-43458-x. View

Jain S, Eadon M . Spatial transcriptomics in health and disease. Nat Rev Nephrol. 2024; 20(10):659-671. PMC: 11392631. DOI: 10.1038/s41581-024-00841-1. View

Li F, Chen Y, Niu A, He Y, Yan Y . Nomogram Model to Predict the Probability of Ovarian Hyperstimulation Syndrome in the Treatment of Patients With Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2021; 12:619059. PMC: 8377671. DOI: 10.3389/fendo.2021.619059. View

Muller T, Finan B, Bloom S, DAlessio D, Drucker D, Flatt P . Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019; 30:72-130. PMC: 6812410. DOI: 10.1016/j.molmet.2019.09.010. View

Dawed A, Mari A, Brown A, McDonald T, Li L, Wang S . Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. Lancet Diabetes Endocrinol. 2022; 11(1):33-41. DOI: 10.1016/S2213-8587(22)00340-0. View

Cena H, Chiovato L, Nappi R . Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. J Clin Endocrinol Metab. 2020; 105(8). PMC: 7457958. DOI: 10.1210/clinem/dgaa285. View

10.

Stern J, Rutkowski J, Scherer P . Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. Cell Metab. 2016; 23(5):770-84. PMC: 4864949. DOI: 10.1016/j.cmet.2016.04.011. View

11.

Teede H, Misso M, Costello M, Dokras A, Laven J, Moran L . Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018; 110(3):364-379. PMC: 6939856. DOI: 10.1016/j.fertnstert.2018.05.004. View

12.

Popoviciu M, Paduraru L, Yahya G, Metwally K, Cavalu S . Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int J Mol Sci. 2023; 24(13). PMC: 10341852. DOI: 10.3390/ijms241310449. View

13.

Khatun M, Arffman R, Lavogina D, Kangasniemi M, Laru J, Ahtikoski A . Women with polycystic ovary syndrome present with altered endometrial expression of stanniocalcin-1†. Biol Reprod. 2019; 102(2):306-315. PMC: 7016287. DOI: 10.1093/biolre/ioz180. View

14.

Jungheim E, Travieso J, Carson K, Moley K . Obesity and reproductive function. Obstet Gynecol Clin North Am. 2012; 39(4):479-93. PMC: 3520133. DOI: 10.1016/j.ogc.2012.09.002. View

15.

Tao X, Zhang X, Ge S, Zhang E, Zhang B . Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide. Int J Clin Exp Pathol. 2015; 8(7):8276-83. PMC: 4555725. View

16.

Khan D, Ojo O, Woodward O, Lewis J, Sridhar A, Gribble F . Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice. Biomolecules. 2022; 12(12). PMC: 9775379. DOI: 10.3390/biom12121736. View

17.

Krasnyi A, Sadekova A, Smolnova T, Chursin V, Buralkina N, Chuprynin V . The Levels of Ghrelin, Glucagon, Visfatin and Glp-1 Are Decreased in the Peritoneal Fluid of Women with Endometriosis along with the Increased Expression of the CD10 Protease by the Macrophages. Int J Mol Sci. 2022; 23(18). PMC: 9499521. DOI: 10.3390/ijms231810361. View

18.

Valverde I, Morales M, Clemente F, Delgado E, Perea A, Villanueva-Penacarrillo M . Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett. 1994; 349(2):313-6. DOI: 10.1016/0014-5793(94)00699-7. View

19.

Mioni R, Chiarelli S, Xamin N, Zuliani L, Granzotto M, Mozzanega B . Evidence for the presence of glucose transporter 4 in the endometrium and its regulation in polycystic ovary syndrome patients. J Clin Endocrinol Metab. 2004; 89(8):4089-96. DOI: 10.1210/jc.2003-032028. View

20.

Vrbikova J, Hill M, Bendlova B, Grimmichova T, Dvorakova K, Vondra K . Incretin levels in polycystic ovary syndrome. Eur J Endocrinol. 2008; 159(2):121-7. DOI: 10.1530/EJE-08-0097. View